Original Query: ALL
Previous Study | Return to List | Next Study
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|ClinicalTrials.gov Identifier: NCT00071838|
Recruitment Status : Completed
First Posted : November 3, 2003
Last Update Posted : July 2, 2017
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:
National Institutes of Health Clinical Center (CC)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||October 4, 2007|
|Study Completion Date :||August 16, 2011|
Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153-87. Review.
Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995 Mar 10;80(5):695-705.